Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Jacquie Ross - Vice President, Investor Relations
Daniel O'Day - Chairman and Chief Executive Officer
Johanna Mercier - Chief Commercial Officer
Merdad Parsey - Chief Medical Officer
Andrew Dickinson - Chief Financial Officer
Cindy Perettie - Executive Vice President, Kite
Conference Call Participants
Evan Seigerman - BMO Capital Markets
Terence Flynn - Morgan Stanley
Daina Graybosch - Leerink Partners
Umer Raffat - Evercore ISI
Carter Gould - Barclays
Michael Yee - Jefferies
Brian Abrahams - RBC Capital Markets
Chris Schott - JPMorgan
Steven Seedhouse - Raymond James
Tim Anderson - Wolf Research
Salveen Richter - Goldman Sachs
Olivia Brayer - Cantor Fitzgerald
Operator
Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared remarks followed by a Q&A session. [Operator Instructions] I'll now hand the call over to Jacquie Ross, Vice President of Investor Relations and Corporate Strategic Finance.
Jacquie Ross
Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the second quarter of 2024. The press release, slides and supplementary data are available on the Investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial Officer, Johanna Mercier; our Chief Medical Officer, Merdad Parsey; and our Chief Financial Officer, Andrew Dickinson. After that, we'll open Q&A where the team will be joined by Cindy Poretti, the Executive Vice President of Kite.
Before we get started, let me remind you that we will be making forward-looking statements. Please refer to Slide 2 regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially.
With that, I'll turn the call over to Dan.
Daniel O'Day
Thank you, Jacquie, and good afternoon, everyone. I’m pleased to share that this was another strong quarter of commercial execution with growth across HIV, Liver Disease, and Oncology. Biktarvy for HIV treatment was up 8% year-over-year, Trodelvy was up 23%, and Cell Therapy was up 11%.
In addition, we continued to demonstrate disciplined operating expense management and delivered exceptional bottom-line growth, highlighting the leverage in our business model. Given the results for the first half of the year, we are raising our non-GAAP operating income and EPS guidance for the full year.